Advancing Oligonucleotide Therapeutics through Bioanalysis
From ASO to siRNA to mRNA. Bioanalysis Built for the Next Generation of Therapeutics.
Technology-agnostic, platform-aligned bioanalysis for every oligonucleotide modality, backed by decades of experience
and trusted by leading biopharma globally.
Expert bioanalysis for
Oligonucleotide Therapeutics
Technology-aligned bioanalytical solutions for all types of oligonucleotides, proteins, and formulations.
Our Expertise
- Decades of experience across modalities
- Specialized in nuanced bioanalysis of:
- Antisense oligonucleotides (ASOs)
- Small interfering RNA (siRNA)
- Messenger RNA (mRNA)
- Antibody oligonucleotide conjugates (AOCs)
- Aptamer-drug conjugates (ApDCs),
- Aptamers, proteins, and more
- Understanding effects of chemical modifications and sequence structure on bioanalysis and overcoming assay challenges
- Expertise across matrices including blood, serum, plasma, urine, CSF, tissues
- PK/TK, PD including RISC Loading, ADA, and ADME
- ADA evaluation via two-step, sandwich or bridging assay formats, tailored to conjugate and payload type – see our Drug Conjugate Modalities page for ADC, AOC and PDC-specific immunogenicity work
Your partner
- Consultative approach with personalized support and dedicated teams and instrumentation for your studies
- Fit-for-purpose assay development depending on stage of development and compliance requirements
- Instrument platform agnostic ensuring study needs are met:
- LC-MS/MS
- LC-HRAM
- Hybridization-based LC-fluorescence
- Hybridization ELISA
- Hybridization MSD
- RT-qPCR, and LBA
- Collaboration to understand modality and formulation, study requirements and endpoints
- Trusted globally by leading biopharma companies
- Extensive regulatory compliance experience with FDA, EMA, ICH (M10), NMPA and NATA
Oligonucleotides and Proteins
There are various types of oligonucleotide therapeutic modalities, including antisense oligonucleotides, siRNA, miRNA.
Oligonucleotide therapeutics are short, synthetic strands of nucleic acids designed to modulate gene expression or protein synthesis. Bioanalysis plays a critical role in characterizing their pharmacokinetics, metabolism, and tissue distribution to support safety and efficacy in drug development.
Resolian’s core team has worked on regulated oligonucleotide bioanalysis since 2006, supporting programs from early in vitro drug screening through to IND/NDA filing studies
Ready to resolve your oligonucleotide bioanalysis challenges?
Partner with a specialist team that understands the unique complexities of nucleic acid therapeutics, from sequence-dependent assay interference to matrix-specific recovery and delivers fit-for-purpose solutions at every stage of development.
Our Oligonucleotides and Proteins Resources
Case Studies
Seeing What Immunoassays Can’t: An Ultra-Sensitive Nano-LC-MS/MS Platform for STAT6 Quantitation
Case Studies
Simple by Design: A Validated 2-in-1 Assay for Acalabrutinib and Its Active Metabolite ACP-5862
Case Studies
A New Sensitivity Benchmark: Ultra-Sensitive Hybrid LC-MS/MS for siRNA Quantitation in Human Plasma
Case Studies
Faster, Simpler Oligonucleotide Quantitation: An Extraction-Free qPCR Workflow for Tissue and Plasma
